Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.
- Surquin, Murielle
- Tielemans, Christian
- Nortier, Joëlle
- Jadoul, Michel
- Peeters, Patrick
- Ryba, Miroslav
- Roznovsky, Ludek
- Doman, József
- Barthelemy, Xavier
- Crasta, Priya Diana
- Messier, Marc
- Houard, Sophie
Publication date
September 2011
DOI Publisher
Informa UK Limited ISSN
1554-8600 Citation count (estimate)
11Abstract
Three doses of the investigational AS02(v)-adjuvanted hepatitis B virus (HBV) vaccine HB-AS02 have been shown to induce more rapid seroprotection and higher anti-HBs antibody concentrations in patients with renal insufficiency than four doses of FENDrix™ (HB-AS04), an adjuvanted HBV vaccine licensed in Europe for use in this population. This study evaluated persistence of immune response up to 36 months after primary vaccination.Clinical Trial, Phase IIIComparative StudyJournal ArticleMulticenter StudyRandomized Controlled TrialSCOPUS: ar.jinfo:eu-repo/semantics/publishe
Add to ORKG